FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2516832486> ?p ?o ?g. }

• W2516832486 abstract "Abstract Introduction: Histone deacetylase (HDAC) inhibitors, by blocking HDAC enzymes, can regulate acetylation states of histones and other non-histone proteins. Hyperacetylation of histones in cells can cause transcriptional activation of tumor suppressor genes, as well as genes involved in cell cycle control, cell division, and apoptosis, resulting in antitumor activity. Currently, 3 HDAC inhibitors (HDACi), vorinostat, romidepsin, and belinostat, are approved for the treatment of relapsed or refractory peripheral or cutaneous T-cell lymphoma (T-CL). HDACi in development also show promising results in B-cell malignancies and solid tumors. Abexinostat, an orally available hydroxamate-containing HDACi with good tolerability, differs from approved HDACi due to its unique pharmacokinetic profile and oral dosing schedule, twice daily 4 hours apart, which allows for continuous exposure at concentrations required for efficient tumor cell killing (Mitsiades, et al. Blood. 2003; unpublished data). Abexinostat may, therefore, offer an active and potentially less-toxic treatment option for cancer with a wider therapeutic index than other HDACi in development. Abexinostat showed manageable toxicity and durable responses, including some complete responses (CR), particularly in patients (pts) with relapsed/refractory follicular lymphoma (FL) (Evens ICML 2013; Morschhauser, Invest New Drugs, 2015). Methods: In this phase 2 trial, pts aged ≥18 years with relapsed/refractory NHL or CLL received oral abexinostat at 80 mg BID for 14 days of a 21-day cycle and continued until progressive disease or unacceptable toxicity. The 80 mg BID dose, which corresponds to the recommended phase 2 dose of 45 mg/m2 BID, was identified in phase 1 of the study (Morschhauser, Invest New Drugs, 2015). The primary endpoint was overall response rate (ORR); secondary endpoints included overall survival, progression-free survival, time to tumor progression, duration of response, disease-free survival, and time to treatment failure. Results: A total of 100 pts (median age, 66.5 years; 52% >65 years; 55% male) were enrolled between Oct 2011 and Jul 2014, including 16 with CLL, 17 with diffuse large B-cell lymphoma (DLBCL), 18 with FL, 16 with mantle cell lymphoma (MCL), 18 with T-CL, and 15 with marginal zone lymphoma (MZL) or other NHL subtypes. The median number of prior regimens across all lymphoma subtypes was 3 (range, 1-11) with a median of 4.5 prior regimens (range, 1-11) for FL pts. All pts received at least one dose of study drug; 55% discontinued due to progressive disease and 25% due to adverse events. Seven pts remain on treatment. Among the 87 pts evaluable for efficacy, ORR was 28% (CR, 5%). Responses by histology are shown in the table. Highest responses were observed in FL, T-CL, and DLBCL with ORRs of 56%, 40%, and 31% and median durations of response of 26.0 weeks (range, 0.1-90.4), 32.1 weeks (range, 6.3-51.3), and 8.1 weeks (range, 3.1-59.0), respectively. Grade ≥3 adverse events (AEs) and any serious AEs (SAEs) were reported in 86% and 46% of pts, respectively. The most frequently reported grade ≥3 treatment-emergent AEs were thrombocytopenia (80%), neutropenia (27%), and anemia (22%). The incidence of any-grade diarrhea was 47% (grade ≥3, 3%). The most commonly reported SAEs included thrombocytopenia (15%), anemia (7%), and pneumonia (6%). The most frequent toxicities that led to discontinuation included hematologic events, such as thrombocytopenia and neutropenia. Gastrointestinal toxicities leading to discontinuation were infrequent with 1 episode of vomiting being reported. Conclusions: Abexinostat has a manageable toxicity profile in pts with various NHL subtypes that is similar to other HDACi and comparable to other single-agent therapies currently in development. Promising efficacy was observed with abexinostat, especially in FL, T-CL, and DLBCL, with an ORR ≥30% in these subtypes, consistent with the results of an independent study of abexinostat in lymphomas that used a week-on-week-off schedule (Evens ICML 2013). Further investigation of the safety and efficacy of abexinostat in these indications implementing the less dose-intense interval on a week-on-week-off schedule is planned. Table. Response With Abexinostat by Tumor Type Tumor type ORR, % (CR, %) Overall (N=87) 28% (5%) FL (n=16) 56% (6%) T-CL (n=15) 40% (7%) DLBCL (n=16) 31% (6%) MCL (n=13) 15% (8%) MZL/other (n=13) 15% (0%) CLL (n=14) 0% (0%) Disclosures Ribrag: Pharmamar: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Off Label Use: abexinostat in NHL and CLL. Coiffier:CELLTRION, Inc.: Consultancy, Honoraria. Luan:Pharmacyclics LLC, an AbbVie Company: Employment. Graef:AbbVie: Equity Ownership; Pharmacyclics LLC, an AbbVie Company: Employment, Membership on an entity's Board of Directors or advisory committees. Morschhauser:Genentech Inc./Roche: Other: Advisory boards." @default.
• W2516832486 created "2016-09-16" @default.
• W2516832486 creator A5003105021 @default.
• W2516832486 creator A5022075377 @default.
• W2516832486 creator A5023792802 @default.
• W2516832486 creator A5032462496 @default.
• W2516832486 creator A5038667383 @default.
• W2516832486 creator A5051605599 @default.
• W2516832486 creator A5055012214 @default.
• W2516832486 creator A5058095468 @default.
• W2516832486 creator A5071885891 @default.
• W2516832486 creator A5088946428 @default.
• W2516832486 date "2015-12-03" @default.
• W2516832486 modified "2023-10-15" @default.
• W2516832486 title "Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study" @default.
• W2516832486 doi "https://doi.org/10.1182/blood.v126.23.256.256" @default.
• W2516832486 hasPublicationYear "2015" @default.
• W2516832486 type Work @default.
• W2516832486 sameAs 2516832486 @default.
• W2516832486 citedByCount "2" @default.
• W2516832486 countsByYear W25168324862016 @default.
• W2516832486 crossrefType "journal-article" @default.
• W2516832486 hasAuthorship W2516832486A5003105021 @default.
• W2516832486 hasAuthorship W2516832486A5022075377 @default.
• W2516832486 hasAuthorship W2516832486A5023792802 @default.
• W2516832486 hasAuthorship W2516832486A5032462496 @default.
• W2516832486 hasAuthorship W2516832486A5038667383 @default.
• W2516832486 hasAuthorship W2516832486A5051605599 @default.
• W2516832486 hasAuthorship W2516832486A5055012214 @default.
• W2516832486 hasAuthorship W2516832486A5058095468 @default.
• W2516832486 hasAuthorship W2516832486A5071885891 @default.
• W2516832486 hasAuthorship W2516832486A5088946428 @default.
• W2516832486 hasConcept C104317684 @default.
• W2516832486 hasConcept C197934379 @default.
• W2516832486 hasConcept C2776202225 @default.
• W2516832486 hasConcept C2776262904 @default.
• W2516832486 hasConcept C2778305200 @default.
• W2516832486 hasConcept C2778375690 @default.
• W2516832486 hasConcept C2781462825 @default.
• W2516832486 hasConcept C502942594 @default.
• W2516832486 hasConcept C55493867 @default.
• W2516832486 hasConcept C64927066 @default.
• W2516832486 hasConcept C71924100 @default.
• W2516832486 hasConcept C86803240 @default.
• W2516832486 hasConcept C98274493 @default.
• W2516832486 hasConceptScore W2516832486C104317684 @default.
• W2516832486 hasConceptScore W2516832486C197934379 @default.
• W2516832486 hasConceptScore W2516832486C2776202225 @default.
• W2516832486 hasConceptScore W2516832486C2776262904 @default.
• W2516832486 hasConceptScore W2516832486C2778305200 @default.
• W2516832486 hasConceptScore W2516832486C2778375690 @default.
• W2516832486 hasConceptScore W2516832486C2781462825 @default.
• W2516832486 hasConceptScore W2516832486C502942594 @default.
• W2516832486 hasConceptScore W2516832486C55493867 @default.
• W2516832486 hasConceptScore W2516832486C64927066 @default.
• W2516832486 hasConceptScore W2516832486C71924100 @default.
• W2516832486 hasConceptScore W2516832486C86803240 @default.
• W2516832486 hasConceptScore W2516832486C98274493 @default.
• W2516832486 hasLocation W25168324861 @default.
• W2516832486 hasOpenAccess W2516832486 @default.
• W2516832486 hasPrimaryLocation W25168324861 @default.
• W2516832486 hasRelatedWork W2004380969 @default.
• W2516832486 hasRelatedWork W2245173676 @default.
• W2516832486 hasRelatedWork W2476666381 @default.
• W2516832486 hasRelatedWork W2519666010 @default.
• W2516832486 hasRelatedWork W2527638889 @default.
• W2516832486 hasRelatedWork W2537189179 @default.
• W2516832486 hasRelatedWork W2544704661 @default.
• W2516832486 hasRelatedWork W2549275035 @default.
• W2516832486 hasRelatedWork W2551008165 @default.
• W2516832486 hasRelatedWork W2556767910 @default.
• W2516832486 hasRelatedWork W2558435593 @default.
• W2516832486 hasRelatedWork W2562287499 @default.
• W2516832486 hasRelatedWork W2577930388 @default.
• W2516832486 hasRelatedWork W2580497378 @default.
• W2516832486 hasRelatedWork W2598110307 @default.
• W2516832486 hasRelatedWork W2918859970 @default.
• W2516832486 hasRelatedWork W2945525803 @default.
• W2516832486 hasRelatedWork W2979660885 @default.
• W2516832486 hasRelatedWork W2982932282 @default.
• W2516832486 hasRelatedWork W2983242185 @default.
• W2516832486 isParatext "false" @default.
• W2516832486 isRetracted "false" @default.
• W2516832486 magId "2516832486" @default.
• W2516832486 workType "article" @default.